This case highlights the significant clinical impact of semaglutide in managing diabetic nephropathy - improving urine albumin creatinine ratio and eGFR, particularly in patients unable to tolerate SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is diabetic kidney disease.